Evidence map›Paper›PMID 31897917›Full record

ArticleInflammation2020

Artesunate ameliorates DSS-induced ulcerative colitis by protecting intestinal barrier and inhibiting inflammatory response.

ShaoJie Yin, HaiFeng Yang, Ya Tao, SiMin Wei, LiuHui Li, MingJiang Liu, JinGui Li

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Review
  5. Current issues in molecular biology · 2026
    Article
  6. Article
  7. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

ShaoJie YinSchool of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, People's Republic of China.
HaiFeng YangJiangsu Agri-animal Husbandry Vocational College, Taizhou, 225300, People's Republic of China.
Ya TaoSchool of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, People's Republic of China.
SiMin WeiSchool of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, People's Republic of China.
LiuHui LiSchool of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, People's Republic of China.
MingJiang LiuSchool of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, People's Republic of China.
JinGui LiSchool of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, People's Republic of China. jingui_li@163.com.ORCID http://orcid.org/0000-0002-0845-0095
Yangzhou University · CNJiangsu Agri-animal Husbandry Vocational College · CN

Funding

National Natural Science Foundation of China 31672595
6 · The paper itself

Abstract

There are very few reports on the protective effect of artesunate (ARS) in ulcerative colitis (UC). This study focused on the efficacy of ARS on intestinal barrier, inflammatory response, and potential mechanism in dextran sulfate sodium (DSS)-induced ulcerative colitis in mice. The results suggested that ARS treatment markedly alleviated DSS-induced clinical symptoms by relieving body weight loss, the disease activity index (DAI) score, and preventing colonic shortening. HE staining and scanning electron microscope analysis revealed that ARS treatment significantly protected the integrity of intestinal barrier through alleviating DSS-induced erosion of surface epithelial cells, reduction of goblet cells, and destruction of the crypt accompanied with inflammatory cells infiltration. Immunofluorescence histochemical staining and western blot assay confirmed that ARS notably inhibited the loss of Muc2 and claudin-1 in mucosal layer with a relative higher level of Bcl-2/Bax ratio and, moreover, inhibited cleaved-caspase-3 expression in colon tissue. In addition, this study reconfirmed the anti-inflammatory function of ARS evidenced by remarkably suppressing the phosphorylation of nuclear factor-κBα (IκBα) and NF-κB p65 and the expression of IL-1β, IL-6, and TNF-α while enhancing IL-10 expression. Taken together, these data highlight that ARS has the protective effect on UC through maintaining the expression of intestinal mucosal barrier-related proteins, suppressing the apoptosis and inflammatory response. This study may facilitate to understand the action mechanism of ARS against UC.

Indexed as

AnimalsAnti-Inflammatory AgentsArtesunateColitis, UlcerativeDextran SulfateFemaleInflammation MediatorsIntestinal MucosaMiceMice, Inbred ICRAnti-Inflammatory AgentsArtesunateDextran SulfateInflammation Mediatorsartesunateinflammationintestinal barrierulcerative colitis

Identifiers

PMID31897917
OpenAlexW2998604631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.